OBJECTIVE: To compare the efficacy of topical gentamycin 0.3% with topical Ciprofloxacin 0.6%, in patients with active Tubotympanic
type of Chronic Suppurative Otitis Media.
STUDY DESIGN: Quasi experimental study.
PLACE AND DURATION: Department of ENT and Head and Neck Surgery Pakistan Institute of Medical Sciences Islamabad from 27th
Sep 2009 to 27th March 2010.
METHODOLOGY: After fulfilling the inclusion criteria 80 patients were recruited in the study, segregated into two equal groups of 40
each by random sampling technique. The patients in group A were offered gentamycin 0.3%, the dose adjusted was 4 drops 8 hourly in
24 hours, while patients in group B were given Ciprofloxacin0.6%, 4 drops 8 hourly in 24 hours, for a period of two weeks. After the said
duration all the patients were called on and enquired about the ear symptoms, followed by the examination of ear by otoscope and
microscope, by visual analogue scale (VAS).
RESULTS: 80 patients were recruited and allocated into two groups of 40 patients each. Out of 40 patientsin group A, 24(60%) were
male having mean age of 27.66 years ± 6.16SDand 16(40%) female having mean age of 27.5 years ± 5.9 SD. From the same number of
patients in group B, 21(52.5%) were male bearing mean age of 30.81 years ± 7.45 SD and 19(47.5%) were female of mean age of 26.0
years ± 6.28 SD. Results showed that out of 40 patients, who were presented with profuse otorrhea in group A, after treatment,
25%(n=10) showed change to moderate otorrhea, 62.5%(n=25) showed a change to mild otorrhea status and 12.5%(n=5) showed no
ear discharge. In group B, the percentage of such patients was 0%, 32.5 %(n=13) and 67.5%(n=27) respectively. The difference
observed was a significant one as determined by applying chi-square test. P value < 0.05 was considered as significant.
CONCLUSION: Topical Ciprofloxacin0.6% is more efficacious and a good option in the treatment of chronic suppurative otitis media
than topical gentamycin 0.3%.
chronic suppurative otitis media, Tubotympanic disease, Topical Ciprofloxacin 0.6%, Topical Gentamycin 0.3%.
Passive social media use and psychological well-being during the COVID-19 pandemic: The role of social comparison and emotion regulation.
Yue Z, Zhang R, Xiao J
Computers in human behavior. 2022; 127(): 107050
Exploring the Alzheimer's disease neuroepigenome: recent advances and future trends.
Zhang H, Elefant F
Neural regeneration research. 2022; 17(2): 325-327
Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44
Differentiating Human Pluripotent Stem Cells to Vascular Endothelial Cells for Regenerative Medicine, Tissue Engineering, and Disease Modeling.
Bertucci T, Kakarla S, Kim D, Dai G
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 1-12
Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease.
Hernandez-Sapiens MA, Reza-ZaldĂvar EE, MĂˇrquez-Aguirre AL, GĂłmez-Pinedo U, Matias-Guiu J, Cevallos RR, Mateos-DĂaz JC, SĂˇnchez-GonzĂˇlez VJ, Canales-Aguirre AA
Neural regeneration research. 2022; 17(1): 31-37